Trial Profile
Regorafenib in Relapsed Glioblastoma REGOMA Study Randomized, Controlled Open-label Phase II Clinical Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Lomustine
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms REGOMA
- 08 Sep 2022 Status changed from active, no longer recruiting to completed.
- 31 Mar 2022 Planned End Date changed from 1 Oct 2021 to 1 Jun 2022.
- 10 Aug 2021 Results assessing the health-related quality of life (HRQoL) assessment, a secondary end-point of the study published in the European Journal of Cancer